A retrospective descriptive study is conducted at the San Juan de Dios Hospital, San José, Costa Rica, during the period from February 2016 to March 2017, with a total of 37 patients from which a combined screening during the first trimester of pregnancy was conducted, evaluating maternal age, biochemical and sonographic methods that together can predict the risk of fetal chromosomal alterations during pregnancy. The purpose of using combined screening as a noninvasive method is to identify high risk gestations and to minimize the number of invasive procedures to detect the highest number of cases. Four patients with higher risk of aneuploidy during pregnancy were identified through this screening.
Introduction
The following paper is based on the results obtained from the application of a first trimester of pregnancy screening tests that suggest fetal aneuploidy, focused in 21, 13, 18 trisomies, Down, Patau and Edwards syndrome respectively with the final goal of educating parents and foresee the causes of associated perinatal morbidity and mortality.
The first trimester of pregnancy echography and structural chromosomic mutation screening protocol is stablished at the unit of obstetrics of Hospital San Juan de Dios and the latter is applied during the period between February 2016 and March 2017. The objective of the screening pretends to reduce the number of invasive procedures during pregnancy that might carry a risk of miscarriage as well as to reduce the monetary costs that this measure generates [1] .
Given that the screening based on maternal age represents a method with a low sensibility and specificity, the combined method that includes variables such as maternal age, biochemical tests and echography altogether has a superior accuracy, achieving index of detection for Trisomy 21 as high as 90% and a 5% of false positives [1] [2] .
The exclusion criteria used to apply the screening method are:
• Younger than 15 years old and older than 35 years old.
• History of aneuploidy as well as congenital malformations or genetic syndrome.
• Pregestational diabetes.
• Epilepsy.
• History of 3 or more abortions.
• Pregnancies achieved through in vitro fertilization.
• Patients exposed to radiation during the first trimester of pregnancy.
All of these exclusion criteria are related to high risk of fetal chromosomic alteration, high risk of metabolic or genetic disease as well as a higher risk of perinatal infection.
The protocol contemplates two types of exploration: the ultrasound between the 11 -13.6 weeks of gestation and biochemical analysis of the beta fraction of the chorionic gonadotropic hormone and a protein associated to pregnancy from maternal blood samples. Both results are expressed as multiples of the me- In case of a positive screening test, it is recommended to perform a fetal karyotype. The elected method is the biopsy of chorionic villi preferably between weeks 11 and 13.6. After week 15 of gestation the gold standard is amniocentesis.
Chorionic villi biopsy must be performed after the 10 th week of gestation either by transabdominal route or by transcervical means depending on the experience and preferences of the physician or the location of the placenta. The complications related to this procedure include the risk of miscarriage (reported between 0.2% and 2% of cases) and vaginal bleeding reported in 10% of cases [1] [5] [6] .
Factors associated with increased risk of miscarriage after chorionic villi biopsy reported in previous retrospective trials include: African Americans, at least two needle aspirations or insertions, abundant bleeding during procedure, maternal age less than 25 years or gestational age less than 10 weeks.
Low levels of PAPP-A are related with placentation-preeclampsia issues, reason why it is also related to higher miscarriage risk [6] .
Amniocentesis must be done after the 15 th week of gestation by transabdo- Eligibility criteria for the procedure are: • High risk for chromosomic fetal alterations.
• High risk of metabolic or genetic diseases.
• High risk of perinatal infection.
Before any invasive procedure, detailed family counsel as well as awareness of associated risks should be done. Using the exclusion criteria, patients followed at San Juan de Dios Hospital from February 2016 to March 2017 were included in our study. A recording data table was created and 41 patients were gathered. From this main group, 4 patients lost their control in our center so at the end 37 patients were finally included.
Methods

Objectives
Perform first trimester screening test to identify asymptomatic individuals at increased risk of having a pregnancy with chromosomic fetal alterations.
Diminish the amount of invasive procedures either by chorionic villi biopsy or amniocentesis that could result in fetal loss.
Results
During the period of February 2016 to March 2017 patients were screened with the combined first trimester screening test during their first trimester of pregnancy. From the 37 included patients three presented risk for trisomy 21 and two presented high risk in the combined test (see Table 1 ).
The group ages go from 26.6 to 44.8 years with an average of 36.18 years of age (see Figure 1 and Figure 2) . 23 of the patients included for screening were Caucasian and 14 had no ethnicity recorded. The screening was performed in patients with pregnancies with gestational ages between 10.4 weeks and 14.2 weeks in average the gestational age was of 12.4 weeks.
The values of the BHCG are located between 0.2 and 2.51 MOM with an average of 0.80 MoM.
The values of PAPP-A were found to be at ranges between 0.27-3.54 MOM with an average of 1.02.
For the sonographic evaluation the nuchal translucency and the cranium rump length (CRL) were recorded and the cases were the nasal bone could be observed were reported ( Table 2 and Table 3 ).
The range of the CRL was 38 -82.34 mm with an average of 62.30 mm. For the nuchal translucency a range between 0.4 and 3.9 with an average of 1.41 mm. The nasal bone was present in 5 of the 37 evaluated fetuses (Figure 3) .
In Figure 4 and Figure 5 the results of the serum analysis from high risk patients are summarized. 
Discussion
The analysis of the results from the combined screening in the first trimester of pregnancy done during one year at Hospital San Juan de Dios, reflects a total of four patients of high risk detected by this protocol. In individuals at risk the average age was of 36 years, which matches with the universal statistics that place increased maternal age as the principal risk correlated to fetal aneuploidy.
It is worth noting that nuchal translucency of one fetus was reported at 3.9, superior to the cut associated with trisomy 21. Nevertheless when following up those cases identified as high risk, after an appropriate counseling to the patients and their family, only one patient was reported and amniocentesis is still pending. Two of the remaining patients rejected the procedure and one of them never came back to prenatal control at the unit, reason why there is a bias of information in this case.
This study concluded 10% of affected cases and, as suggested by foreign sources, in our environment amniocentesis will be performed on the patient who accepted the procedure, corresponding respectively to 1.85% of the screened patients.
Since we practice in social care and our country has limited economical resources, the screening is made on selected patients with inclusion risk criteria that might implicate an increased risk for the gestation, reason why the sample is not significant.
Actually in other countries, a free cell on maternal blood DNA analysis is be- It has been shown that this method is feasible for routine screening and allows a reliable diagnosis of aneuploidy, with false-positive rates significantly lower than those of combined screening [12] [13].
Although this screening method is not publicly available, it is ideal for all pregnant patients to have at least one first-trimester ultrasound that includes the measurement of the nuchal translucency, which is a marker not only of fetal chromosomal alterations but also of cardiac defects and other genetic syndromes.
Conclusions
The combined screening of the first trimester of pregnancy represents an adequate screening strategy in this population to fundamentally reduce invasive diagnostic procedures and their complications in the case of suspected aneuploidy in the fetus.
In our study, despite being a sample of high-risk pregnant women, 4 patients with a risk of chromosomopathies were detected, which equal 10% of the study population, concordant with published data and demonstrating that counseling for just as screening is essential for the final follow-up of these patients.
This confirms that ultrasound aimed at screening patients with some risk in the first trimester of pregnancy should be a fundamental and mandatory study as a measure even of initial uptake of the patient during a pregnancy and, when combined with other epidemiological variables and biophysical in this population, we stratify the individual risk early on in each patient and thus we can offer a higher quality care in this very determinant stage of being a human being.
